Skip to Content

Post hoc analysis shows a clear correlation between high expression of PDL1 and efficacy of cemiplimab

At WCLC 2020, Dr Saadettin Kilickap reported the results of a post hoc analysis of the phase III EMPOWER-Lung 1 trial evaluating cemiplimab vs platinum-doublet chemotherapy as a frontline treatment in 437 patients with advanced NSCLC with a PD-L1 level ≥ 50%.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top